Impact of TP53 Mutations on Outcome in EGFR -Mutated Patients Treated with First-Line Tyrosine Kinase Inhibitors

New Guidelines to Evaluate the Response to Treatment in Solid Tumors

Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660

Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma

Mok, T. S., Wu, Y.-L., Thongprasert, S., Yang, C.-H., Chu, D.-T., Saijo, N., Sunpaweravong, P., Han, B., Margono, B., Ichinose, Y., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810699 · Cited by 8,261

p53, the cellular gatekeeper for growth and division

Levine, A. J. (1997) · Cell · doi:10.1016/s0092-8674(00)81871-1 · Cited by 7,693

Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR

Maemondo, M., Inoue, A., Kobayashi, K., Sugawara, S., Oizumi, S., Isobe, H., Gemma, A., Harada, M., Yoshizawa, H., Kinoshita, I., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0909530 · Cited by 5,525

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial

Rosell, R., Carcereny, E., Gervais, R., Vergnenegre, A., Massuti, B., Felip, E., Palmero, R., Garcia-Gomez, R., Pallares, C., Sanchez, J. M., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70393-x · Cited by 5,489

Transcriptional control of human p53-regulated genes

Riley, T., Sontag, E., Chen, P., & Levine, A. (2008) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2395 · Cited by 1,921

Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials

Yang, J. C.-H., Wu, Y.-L., Schuler, M., Sebastian, M., Popat, S., Yamamoto, N., Zhou, C., Hu, C.-P., O'Byrne, K., Feng, J., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(14)71173-8 · Cited by 1,574

KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib

Pao, W. J., Wang, T. Y., Riely, G. J., Miller, V. A., Pan, Q., Ladanyi, M., Zakowski, M. F., Heelan, R. T., Kris, M. G., & VARMUS, H. E. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020017 · Cited by 1,517

Mutations of the Epidermal Growth Factor Receptor Gene Predict Prolonged Survival After Gefitinib Treatment in Patients With Non–Small-Cell Lung Cancer With Postoperative Recurrence

Mitsudomi, T., Kosaka, T., Endoh, H., Horio, Y., Hida, T., Mori, S., Hatooka, S., Shinoda, M., Takahashi, T., & Yatabe, Y. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.00.992 · Cited by 940

TP53 Mutations and Survival in Squamous-Cell Carcinoma of the Head and Neck

Poeta, M. L., Manola, J. B., Goldwasser, M. A., Forastiere, A. A., Benoit, N. E., Califano, J. A., Ridge, J. A., Goodwin, J. W., Kenady, D. E., Saunders, J., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa073770 · Cited by 818

Genomic Landscape and Tumor Mutational Burden Determination of Circulating Tumor DNA in Over 5,000 Chinese Patients with Lung Cancer

Shi, J., Wang, Z., Zhang, J., Xu, Y., Xiao, X., Quan, X., Bai, Y., Yang, X., Ming, Z., Guo, X., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-1537 · Cited by 20

Efficacy and Resistance of Afatinib in Chinese Non-Small Cell Lung Cancer Patients With HER2 Alterations: A Multicenter Retrospective Study

Song, Z., Lv, D., Chen, S., Huang, J., Wang, L., Xu, S., Chen, H., Wang, G., & Lin, Q. D. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.657283 · Cited by 21

A Nationwide Study on the Impact of Routine Testing for EGFR Mutations in Advanced NSCLC Reveals Distinct Survival Patterns Based on EGFR Mutation Subclasses

Koopman, B., Garcia, B. N. C., Kuijpers, C. C. H. J., Damhuis, R. A. M., van der Wekken, A. J., Groen, H. J. M., Schuuring, E. M. D., Willems, S. M., & van Kempen, L. C. L. T. (2021) · Cancers · doi:10.3390/cancers13143641 · Cited by 22

Domain-specific p53 mutants activate EGFR by distinct mechanisms exposing tissue-independent therapeutic vulnerabilities

Ho, T. L. F., Lee, M. Y., Goh, H. C., Ng, G. Y. N., Lee, J. J. H., Kannan, S., Lim, Y. T., Zhao, T., Lim, E. K. H., Phua, C. Z. J., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-37223-3 · Cited by 21

Combination of genomic instability score and TP53 status for prognosis prediction in lung adenocarcinoma

Feng, J., Lan, Y., Liu, F., Yuan, Y., Ge, J., Wei, S., Luo, H., Li, J., Luo, T., & Bian, X. (2023) · npj Precision Oncology · doi:10.1038/s41698-023-00465-x · Cited by 22

TP53 mutations in circulating tumor DNA in advanced epidermal growth factor receptor-mutant lung adenocarcinoma patients treated with gefitinib

Yu, R., Bai, H., Li, T., Gao, B., Han, J., Chang, G., Zhang, P., Fei, K., He, X., & Wang, J. (2021) · Translational Oncology · doi:10.1016/j.tranon.2021.101163 · Cited by 22

Concomitant genetic alterations are associated with response to EGFR targeted therapy in patients with lung adenocarcinoma

Chen, H., Liu, M., Dai, Z., Li, S., Luo, Y., Wang, Y., Su, W., Cai, W., Yang, D., Huang, J., et al. (2020) · Translational Lung Cancer Research · doi:10.21037/tlcr-20-679 · Cited by 18

Plasma Predictive Features in Treating EGFR-Mutated Non-Small Cell Lung Cancer

Steendam, C. M. J., Veerman, G., Pruis, M. A., Atmodimedjo, P. N., Paats, M. S., van der Leest, C., von der Thüsen, J. H., Yick, D. C. Y., Hoop, E. O., Koolen, S. L. W., et al. (2020) · Cancers · doi:10.3390/cancers12113179 · Cited by 21

Computer-Aided Nodule Assessment and Risk Yield (CANARY) may facilitate non-invasive prediction of EGFR mutation status in lung adenocarcinomas

Clay, R., Kipp, B. R., Jenkins, S. M., Karwoski, R. A., Maldonado, F., Rajagopalan, S., Voss, J. S., Bartholmai, B. J., Aubry, M. C., & Peikert, T. (2017) · Scientific Reports · doi:10.1038/s41598-017-17659-6 · Cited by 20

Profiling of circulating tumor DNA in plasma of non‐small cell lung cancer patients, monitoring of epidermal growth factor receptor p.T790M mutated allelic fraction using beads, emulsion, amplification, and magnetics companion assay and evaluation in future application in mimicking circulating tumor cells

Garcia, J., Wozny, A., Geiguer, F., Delherme, A., Barthélémy, D., Merle, P., Tissot, C., Jones, F. S., Johnson, C., Xing, X., et al. (2019) · Cancer Medicine · doi:10.1002/cam4.2244 · Cited by 20

Epidermal growth factor receptor tyrosine kinase inhibitors in advanced nonsmall cell lung cancer: what is the preferred first-line therapy?

Roeper, J., & Griesinger, F. (2018) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000495 · Cited by 19

Sequencing Therapy for Genetically Defined Subgroups of Non–Small Cell Lung Cancer

Yu, H. A., Planchard, D., & Lovly, C. M. (2018) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_201331 · Cited by 20

Does TMB Impact the Effectiveness of TKIs in EGFR-Mutant NSCLC?

Cheng, M. L., & Oxnard, G. R. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-2368 · Cited by 19

Non-disruptive mutation in TP53 DNA-binding domain is a beneficial factor of esophageal squamous cell carcinoma

Huang, M., Jin, J., Zhang, F., Wu, Y., Xu, C., Ying, L., & Su, D. (2020) · Annals of Translational Medicine · doi:10.21037/atm.2020.02.142 · Cited by 18

Low frequency of mutation of epidermal growth factor receptor (EGFR) and arrangement of anaplastic lymphoma kinase (ALK) in primary pulmonary lymphoepithelioma‐like carcinoma

Yin, K., Feng, H., Li, L., Chen, Y., Xie, Z., Lv, Z., Guo, W., Lu, D., Yang, X., Yan, W., et al. (2019) · Thoracic Cancer · doi:10.1111/1759-7714.13271 · Cited by 19

Co-Occurring Alterations of ERBB2 Exon 20 Insertion in Non-Small Cell Lung Cancer (NSCLC) and the Potential Indicator of Response to Afatinib

Yuan, B., Zhao, J., Zhou, C., Wang, X., Zhu, B., Zhuo, M., Dong, X.-L., Feng, J., Yi, C., Yang, Y., et al. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00729 · Cited by 17

Concurrent TP53 mutations predict a poor prognosis of EGFR‑mutant NSCLCs treated with TKIs: An updated systematic review and meta‑analysis

Lan, B., Zhao, N., Du, K., & Leng, B. (2022) · Oncology Letters · doi:10.3892/ol.2022.13504 · Cited by 22

Co-occurring genetic alterations predict distant metastasis and poor efficacy of first-line EGFR-TKIs in EGFR-mutant NSCLC

Deng, L., Gao, G., Deng, H.-B., Wang, F., Wang, Z., & Yu, Y. (2019) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-019-03001-2 · Cited by 18

P53-Related Anticancer Activities of Drimia calcarata Bulb Extracts Against Lung Cancer

Laka, K., & Mbita, Z. (2022) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2022.876213 · Cited by 17

Successful Response to Osimertinib Rechallenge after Intervening Chemotherapy in an EGFR T790M-Positive Lung Cancer Patient

Metro, G., Baglivo, S., Siggillino, A., Ludovini, V., Chiari, R., Rebonato, A., & Bellezza, G. (2018) · Clinical Drug Investigation · doi:10.1007/s40261-018-0691-8 · Cited by 17

A computed tomography (CT)-derived radiomics approach for predicting primary co-mutations involving TP53 and epidermal growth factor receptor (EGFR) in patients with advanced lung adenocarcinomas (LUAD)

Zhu, Y., Guo, Y., Xu, D., Zhang, J., Liu, Z., Wu, X., Yang, X., Chang, D., Xu, M., Yan, J., et al. (2021) · Annals of Translational Medicine · doi:10.21037/atm-20-6473 · Cited by 17

Effect of timing, technique and molecular features on brain control with local therapies in oncogene-driven lung cancer

Shafie, R. A. E., Seidensaal, K., Bozorgmehr, F., Kazdal, D. N., Eichkorn, T., Elshiaty, M., Weber, D., Allgäuer, M., König, L., Lang, K., et al. (2021) · ESMO Open · doi:10.1016/j.esmoop.2021.100161 · Cited by 18

Emerging uses of biomarkers in lung cancer management: molecular mechanisms of resistance

Attarian, S., Rahman, N., & Halmos, B. (2017) · Annals of Translational Medicine · doi:10.21037/atm.2017.07.18 · Cited by 17

The Therapeutic Potential of the Restoration of the p53 Protein Family Members in the EGFR-Mutated Lung Cancer

Fregni, M., Ciribilli, Y., & Zawacka‐Pankau, J. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23137213 · Cited by 16

Non‑invasive detection of EGFR and TP53�mutations through the combination of plasma, urine and sputum in advanced non‑small cell lung cancer

Wu, Z., Yang, Z., Li, C., Zhao, W. M., Liang, Z., Dai, Y., Zeng, J., Zhu, Q., Miao, K., Cui, D., et al. (2019) · Oncology Letters · doi:10.3892/ol.2019.10726 · Cited by 16

Mefatinib as first-line treatment of patients with advanced EGFR-mutant non-small-cell lung cancer: a phase Ib/II efficacy and biomarker study

Wang, P., Li, Y., Lv, D., Yang, L., Ding, L., Zhou, J., Hong, W., Chen, Y., Zhang, D., He, S., et al. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00773-3 · Cited by 17

PTEN Loss as a Predictor of Tumor Heterogeneity and Poor Prognosis in Patients With EGFR-mutant Advanced Non–small-cell Lung Cancer Receiving Tyrosine Kinase Inhibitors

Ferrara, M. G., Martini, M., D’Argento, E., Forcella, C., Vita, E., Noia, V. D., Sperduti, I., Bilotta, M., Ribelli, M., Damiano, P., et al. (2021) · Clinical Lung Cancer · doi:10.1016/j.cllc.2020.12.008 · Cited by 16

Anlotinib plus icotinib as a potential treatment option for EGFR-mutated advanced non-squamous non-small cell lung cancer with concurrent mutations: final analysis of the prospective phase 2, multicenter ALTER-L004 study

Zhang, L., Wang, L., Wang, J., Chen, J., Meng, Z., Liu, Z., Jiang, X., Wang, X., Huang, C., Chen, P., et al. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01823-w · Cited by 15

Co‐mutational assessment of circulating tumour DNA (ctDNA) during osimertinib treatment for T790M mutant lung cancer

Xing, P., Han, X., Wang, S., Liu, Y., Yang, S., Hao, X., Wang, Y., Liu, P., Li, J., Wang, L., et al. (2019) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.14565 · Cited by 14

Effect of Combining EGFR Tyrosine Kinase Inhibitors and Cytotoxic Agents on Cholangiocarcinoma Cells

Boonsri, B., Yacqub‐Usman, K., Thintharua, P., Myint, K. Z., Sae-lao, T., Collier, P., Suriyonplengsaeng, C., Larbcharoensub, N., Balasubramanian, B., Venkatraman, S., et al. (2020) · Cancer Research and Treatment · doi:10.4143/crt.2020.585 · Cited by 15

Tumor genomics and response to chemotherapy in advanced non-small cell lung cancer with exon 20 insertion epidermal growth factor receptor mutations

Wang, Y., Li, J., Zhou, Y., Cao, S., Ling, X., Zhang, Y., Nie, W., & Zhong, H. (2020) · Annals of Translational Medicine · doi:10.21037/atm-20-6172 · Cited by 14

Unique Genomic Alterations of Cerebrospinal Fluid Cell-Free DNA Are Critical for Targeted Therapy of Non-Small Cell Lung Cancer With Leptomeningeal Metastasis

Wang, Y., Jiang, F., Xia, R., Li, M., Yao, C., Li, Y., Li, H., Zhao, Q., Shi, M., Yu, Y., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.701171 · Cited by 16

Potential predictive value of serum targeted metabolites and concurrently mutated genes for EGFR-TKI therapeutic efficacy in lung adenocarcinoma patients with EGFR sensitizing mutations.

Han, X., Luo, R., Wang, L., Zhang, L., Wang, T., Zhao, Y., Xiao, S., Qiao, N., Xu, C., Ding, L., et al. (2020) · PubMed Central · Cited by 15

Driver gene alterations profiling of Chinese non‐small cell lung cancer and the effects of co‐occurring alterations on immunotherapy

Sun, S., Du, W., Sun, Q., Zhao, X. Q., Qin, B., Shi, D., Wan, C., & Wu, Z. (2021) · Cancer Medicine · doi:10.1002/cam4.4178 · Cited by 13

A special prognostic indicator: tumor mutation burden combined with immune infiltrates in lung adenocarcinoma with TP53 mutation

Fu, J., Li, Y., Li, C., Tong, Y., Li, M., & Cang, S. (2021) · Translational Cancer Research · doi:10.21037/tcr-21-565 · Cited by 14

Efficacy and safety analyses of epidermal growth factor receptor tyrosine kinase inhibitors combined with chemotherapy in the treatment of advanced non–small-cell lung cancer with an EGFR/TP53 co-mutation

Shang, K., Huang, H., Xu, Y., Liu, Y., Lu, Z., & Chen, L. (2022) · BMC Cancer · doi:10.1186/s12885-022-10391-z · Cited by 13

Phase 2 study of afatinib among patients with recurrent and/or metastatic esophageal squamous cell carcinoma

Hong, M. H., Heo, S. G., Lee, Y., Kim, H. S., Park, K. U., Kim, H., Ko, Y. H., Chung, I., Min, Y. J., Kim, M. K., et al. (2020) · Cancer · doi:10.1002/cncr.33123 · Cited by 14

Detection of Low-Frequency KRAS Mutations in cfDNA From EGFR-Mutated NSCLC Patients After First-Line EGFR Tyrosine Kinase Inhibitors

Nardo, G., Carlet, J., Marra, L., Bonanno, L., Boscolo, A., Maso, A. D., Bragadin, A. B., Indraccolo, S., & Zulato, E. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2020.607840 · Cited by 14

CP-673451, a Selective Platelet-Derived Growth Factor Receptor Tyrosine Kinase Inhibitor, Induces Apoptosis in Opisthorchis viverrini-Associated Cholangiocarcinoma via Nrf2 Suppression and Enhanced ROS

Duangdara, J., Boonsri, B., Sayinta, A., Supradit, K., Thintharua, P., Kumkate, S., Suriyonplengsaeng, C., Larbcharoensub, N., Mingphruedhi, S., Rungsakulkij, N., et al. (2023) · Pharmaceuticals · doi:10.3390/ph17010009 · Cited by 13

The Role of p53 Expression in Patients with RAS/BRAF Wild-Type Metastatic Colorectal Cancer Receiving Irinotecan and Cetuximab as Later Line Treatment

Ziranu, P., Lai, E., Schirripa, M., Puzzoni, M., Persano, M., Pretta, A., Munari, G., Liscia, N., Pusceddu, V., Loupakis, F., et al. (2021) · Targeted Oncology · doi:10.1007/s11523-021-00816-3 · Cited by 15

Co-occurring MET Amplification Predicts Inferior Clinical Response to First-Line Erlotinib in Advanced Stage EGFR-Mutated NSCLC Patients

Clement, M. S., Ebert, E. B. F., Meldgaard, P., & Sørensen, B. S. (2021) · Clinical Lung Cancer · doi:10.1016/j.cllc.2021.05.002 · Cited by 13

Prognosis of ALK-rearranged non-small-cell lung cancer patients carrying TP53 mutations

Canale, M., Petracci, E., Cravero, P., Mariotti, M., Minuti, G., Metro, G., Ludovini, V., Baglivo, S., Puccetti, M., Dubini, A., et al. (2022) · Translational Oncology · doi:10.1016/j.tranon.2022.101471 · Cited by 16

Liquid biopsy comprehensive genomic profiling of lung cancer in the Italian population: A real-world experience

Porta, C., Pradelli, L., Sicari, E., Castellani, S., Sivakumar, S., Sokol, E. S., Montesion, M., Wieland, T., Rambichler, J., Minari, R., et al. (2023) · Lung Cancer · doi:10.1016/j.lungcan.2023.107359 · Cited by 12

Transformation to small cell lung cancer and activation of KRAS during long‑term erlotinib maintenance in a patient with non‑small cell lung cancer: A case report

Gu, Y., Zhu, X., Cao, B., Wu, X., Tong, X., Shao, Y. W., & Liang, L. (2019) · Oncology Letters · doi:10.3892/ol.2019.10196 · Cited by 12

Plasma EGFR mutation abundance affects clinical response to first-line EGFR-TKIs in patients with advanced non-small cell lung cancer

Wang, X., Liu, Y., Meng, Z., Wu, Y., Wang, S., Jin, G., Qin, Y., Wang, F., Wang, J., Zhou, H., et al. (2021) · Annals of Translational Medicine · doi:10.21037/atm-20-7155 · Cited by 11

Biological and therapeutic implications of the cancer-related germline mutation landscape in lung cancer

Panagiotou, Ε., Vathiotis, I. A., Makrythanasis, P., Hirsch, F. R., Sen, T., & Syrigos, K. (2024) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(24)00124-3 · Cited by 11

Current Biomarkers in Non-Small Cell Lung Cancer—The Molecular Pathologist’s Perspective

Steinestel, K., & Arndt, A. (2025) · Diagnostics · doi:10.3390/diagnostics15050631 · Cited by 13

Successful osimertinib rechallenge following subsequent chemotherapy regimen in a patient with metastatic non-small cell lung carcinoma: a case report

Han, Z., Luo, N., Li, L., & Liu, Z.-L. (2021) · Annals of Palliative Medicine · doi:10.21037/apm-20-2369 · Cited by 11

Pilot Study of Dacomitinib for Patients With Metastatic EGFR-Mutant Lung Cancers With Disease Progression After Initial Treatment With Osimertinib

Choudhury, N. J., Makhnin, A., Tobi, Y. Y., Daly, R. M., Preeshagul, I. R., Iqbal, A. N., Ahn, L. S. H., Hayes, S. A., Heller, G., Kris, M. G., et al. (2021) · JCO Precision Oncology · doi:10.1200/po.21.00005 · Cited by 11

Landscape of Genomic Alterations and PD-L1 Expression in Early-Stage Non-Small-Cell Lung Cancer (NSCLC)—A Single Center, Retrospective Observational Study

Stephan-Falkenau, S., Streubel, A., Mairinger, T., Kollmeier, J., Misch, D., Thiel, S., Bauer, T. T., Pfannschmidt, J., Hollmann, M., Wessolly, M., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232012511 · Cited by 12

High MAF of EGFR mutations and high ratio of T790M sensitizing mutations in ctDNA predict better third‐generation TKI outcomes

Li, Y., Zhang, F., Yuan, P., Guo, L., Jianming, Y., & He, J. (2020) · Thoracic Cancer · doi:10.1111/1759-7714.13418 · Cited by 11

Thyroid cancer harboring PTEN and TP53 mutations: A peculiar molecular and clinical case report

Colombo, C., Pogliaghi, G., Tosi, D., Muzza, M., Bulfamante, G., Persani, L., Fugazzola, L., & Cirello, V. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.949098 · Cited by 11

Impact of PD-L1 Expression on the Overall Survival of Caucasian Patients with Advanced EGFR-Mutant NSCLC Treated with Frontline Osimertinib

Papazyan, T., Denis, M. G., Sagan, C., Raimbourg, J., Herbreteau, G., & Tostivint, E. P. (2024) · Targeted Oncology · doi:10.1007/s11523-024-01072-x · Cited by 11

Persist or resist: Immune checkpoint inhibitors in EGFR ‐mutated NSCLC

Zhu, P., Li, Z., Sun, Y., Liu, T., & Yin, R. H. (2024) · Cancer Science · doi:10.1111/cas.16428 · Cited by 10

Overall Survival Benefits of First-Line Treatments for Asian Patients With Advanced EGFR-Mutated NSCLC Harboring L858R Mutation: A Systematic Review and Network Meta-Analysis

Chan, S.-K., Choi, C., & Lee, V. H.-F. (2022) · JTO Clinical and Research Reports · doi:10.1016/j.jtocrr.2022.100322 · Cited by 10

Mechanisms of resistance and correlation between pre-treatment co-alterations and p-prognosis to osimertinib in chemo-naïve advanced non-small cell lung cancer

Tamiya, A., Osuga, M., Harada, D., Isa, S., Taniguchi, Y., Nakamura, K., Mizumori, Y., Shinohara, T., Yanai, H., Nakatomi, K., et al. (2024) · Lung Cancer · doi:10.1016/j.lungcan.2024.107917 · Cited by 9

Chromosomal Instability Is Associated with cGAS–STING Activation in EGFR-TKI Refractory Non-Small-Cell Lung Cancer

Yonesaka, K., Kurosaki, T., Tanizaki, J., Kawakami, H., Tanaka, K., Maenishi, O., Takamura, S., Sakai, K., Chiba, Y., Teramura, T., et al. (2025) · Cells · doi:10.3390/cells14060447 · Cited by 9

EGFR-TKI Combined with Pemetrexed versus EGFR-TKI Monotherapy in Advanced EGFR-Mutated NSCLC: A Prospective, Randomized, Exploratory Study

Gu, W., Zhang, H., Lu, Y., Li, M., Yang, S., Liang, J., Ye, Z., Li, Z., He, M., Shi, X., et al. (2023) · Cancer Research and Treatment · doi:10.4143/crt.2022.1438 · Cited by 9

A clinical decision support system to predict the efficacy for EGFR-TKIs based on artificial neural network

Xiao, L., Guan, R., Zhu, J., Meng, Y., Zhu, J., Yang, Y., Cui, Y., Dai, J., Mao, W., Lv, L., et al. (2023) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-023-05104-3 · Cited by 10

Temporal genomic heterogeneity guiding individualized therapy in recurrent non-small cell lung cancer

Fang, Q., Wan, X., D’Aiello, A., Sun, H., Gu, W., Li, Y., Zhou, C., Xie, B., Deng, Q., Cheng, H., et al. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1116809 · Cited by 9

Larger tumors are associated with inferior progression‐free survival of first‐line EGFR‐tyrosine kinase inhibitors and a lower abundance of EGFR mutation in patients with advanced non‐small cell lung cancer

Pan, Y., Gao, G., Chen, X., Tian, Q., Wu, F., Liu, Q., Wang, Y., Jiang, T., Liu, Y., Li, X., et al. (2019) · Thoracic Cancer · doi:10.1111/1759-7714.12986 · Cited by 9

Proposal of real-world solutions for the implementation of predictive biomarker testing in patients with operable non-small cell lung cancer

Hofman, P. M., Christopoulos, P., D’Haene, N., Gosney, J. R., Normanno, N., Schuuring, E. M. D., Tsao, M., Quinn, C. M., Russell, J., Keating, K. E., et al. (2025) · Lung Cancer · doi:10.1016/j.lungcan.2025.108107 · Cited by 8

Clinical factors and molecular co-alterations impact outcomes in patients receiving first-line osimertinib for EGFR-mutated non-small cell lung cancer

Sun, F., Banwait, M. K., Singhal, S., Herrmann, A. C., Piotrowska, Z., Yun, K. M., Bazhenova, L. A., Ullah, A. T., Guo, E. W., Wakelee, H. A., et al. (2025) · Lung Cancer · doi:10.1016/j.lungcan.2025.108747 · Cited by 9

Lung Cancer in Li-Fraumeni Syndrome

Kerrigan, K. C., Chan, J., Vagher, J., Kohlmann, W. K., Naumer, A., Anson, J., Low, S., Schiffman, J. D., & Maese, L. D. (2021) · JCO Precision Oncology · doi:10.1200/po.20.00468 · Cited by 8

Case report: primary resistance to osimertinib in erlotinib-pretreated lung adenocarcinoma with EGFR T790 M mutation

Zheng, L., Chen, L., Liao, X., Xu, Z., Chen, Z., & Sun, J. (2018) · BMC Cancer · doi:10.1186/s12885-018-4991-4 · Cited by 8

De Novo Versus Secondary Metastatic EGFR-Mutated Non-Small-Cell Lung Cancer

Bozorgmehr, F., Kazdal, D. N., Chung, I., Kirchner, M., Magios, N., Kriegsmann, M., Allgäuer, M., Klotz, L. V., Muley, T., Shafie, R. A. E., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.640048 · Cited by 8

Landscape of EGFR mutations in lung adenocarcinoma: a single institute experience with comparison of PANAMutyper testing and targeted next-generation sequencing

Lee, J., Han, Y. B., Kwon, H. J., Lee, S. K., Kim, H., & Chung, J.-H. (2022) · Journal of Pathology and Translational Medicine · doi:10.4132/jptm.2022.06.11 · Cited by 8

Multiple single cell screening and DNA MDA amplification chip for oncogenic mutation profiling

Li, R., Zhou, M., Yue, C., Zhang, W., Ma, Y., Peng, H., Hu, Z., & Wei, Z. (2018) · Lab on a Chip · doi:10.1039/c7lc00924k · Cited by 8

Co-occurring genetic alterations and primary EGFR T790M mutations detected by NGS in pre-TKI-treated NSCLCs

Tang, Y., Che, N., Yu, Y., Gao, Y., Shi, H., Feng, Q. F., Wei, B., Ma, L., Gao, M., Ma, J., et al. (2019) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-019-03065-0 · Cited by 8

A pulmonary enteric adenocarcinoma patient harboring a rare EGFR exon 19 P753S mutation: Case report and review

Xu, X., Chen, D., Wu, X. J., & Wang, Q. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.988625 · Cited by 7

Prognostic impact of tumour mutational burden in resected stage I and II lung adenocarcinomas from a European Thoracic Oncology Platform Lungscape cohort

Bubendorf, L., Zoche, M., Dafni, U. G., Rüschoff, J. H., Prince, S. S., Marti, N., Stavrou, A., Kammler, R., Finn, S. P., Moch, H., et al. (2022) · Lung Cancer · doi:10.1016/j.lungcan.2022.09.014 · Cited by 7

Prediction of EGFR-TP53 genes co-mutations in patients with lung adenocarcinoma (LUAD) by 18F-FDG PET/CT radiomics

Li, S., Hu, Y., Tian, C., Luan, J., Zhang, X., Wei, Q., Li, X., & Bian, Y. (2024) · Clinical & Translational Oncology · doi:10.1007/s12094-024-03685-0 · Cited by 8

Mutation patterns and evolutionary action score of TP53 enable identification of a patient population with poor prognosis in advanced non‐small cell lung cancer

Jiang, W., Cheng, H., Yu, L., Zhang, J., Wang, Y., Liang, Y., Lou, F., Wang, H., & Cao, S. (2022) · Cancer Medicine · doi:10.1002/cam4.5447 · Cited by 8

Genomic features and its potential implication in bone oligometastatic NSCLC

Liao, R., Yi, G., Shen, L., Zhang, X., Xu, Z., Peng, Y., & Yang, Z. (2023) · BMC Pulmonary Medicine · doi:10.1186/s12890-023-02354-2 · Cited by 6

Consistency of genotyping data from simultaneously collected plasma circulating tumor DNA and tumor-DNA in lung cancer patients

Zhang, J., Dong, A., Li, S., Ren, X., & Zhang, X. (2020) · Journal of Thoracic Disease · doi:10.21037/jtd-20-3162 · Cited by 7

Osimertinib plus chemotherapy versus osimertinib for patients with advanced NSCLC with concomitant EGFR and TP53 mutations: a prospective cohort study

Li, J., Zhan, X., Shao, M., Zeng, R., Li, J., Zhu, H., Feng, A., Yang, Z., & Jing, W. (2025) · Scientific Reports · doi:10.1038/s41598-025-03422-9 · Cited by 6

TP53 Exon 5 Mutation Indicates Poor Progression-Free Survival for Patients with Stage IV NSCLC

Feng, H., Xu, H., Shi, X., Ding, G., Yan, C., Li, L., Jian, Z., Yang, X., Guo, H., Feng, L., et al. (2023) · Frontiers in Bioscience-Landmark · doi:10.31083/j.fbl2807147 · Cited by 6

Prevalence and Associations of Co-occurrence of NFE2L2 Mutations and Chromosome 3q26 Amplification in Lung Cancer

Liu, J., Liu, S., Li, D., Li, H., & Zhang, F. (2024) · Global Medical Genetics · doi:10.1055/s-0044-1786004 · Cited by 6

D-Propranolol Impairs EGFR Trafficking and Destabilizes Mutant p53 Counteracting AKT Signaling and Tumor Malignancy

Barra, J., Cerda‐Infante, J., Sandoval, L., Gajardo-Meneses, P., Henriquez, J. F., Labarca, M., Metz, C., Venegas, J., Retamal, C., Oyanadel, C., et al. (2021) · Cancers · doi:10.3390/cancers13143622 · Cited by 6

High Tumor Mutation Burden Is Associated with Poor Clinical Outcome in EGFR-Mutated Lung Adenocarcinomas Treated with Targeted Therapy

Sung, J., Park, D.-W., & Lee, S. H. (2022) · Biomedicines · doi:10.3390/biomedicines10092109 · Cited by 6

The heterogeneous impact of targeted therapy on the prognosis of stage III/IV colorectal cancer patients with different subtypes of TP53 mutations

Chen, J., Chang, X., Li, X., Liu, J., Wang, N., Wu, Y., Zheng, L., & Nie, X. (2023) · Cancer Medicine · doi:10.1002/cam4.6766 · Cited by 5

Quantitative modeling of tumor dynamics and development of drug resistance in non‐small cell lung cancer patients treated with erlotinib

Yin, A., Veerman, G., van Hasselt, J. G. C., Steendam, C. M. J., Dubbink, H. J., Guchelaar, H., Friberg, L. E., Dingemans, A. C., Mathijssen, R. H. J., & Moes, D. J. A. R. (2024) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.13105 · Cited by 6

Nicotinamide in Combination with EGFR-TKIs for the Treatment of Stage IV Lung Adenocarcinoma with EGFR Mutations: A Randomized Double-Blind (Phase IIb) Trial

Oh, H., Bae, S., Oh, I., Park, C., Jung, K.-M., Kim, D.-M., Lee, J.-W., Kang, C. K., Park, I. Y., & Kim, Y. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-3059 · Cited by 6

Influence of TP53 mutation on efficacy and survival in advanced EGFR‐mutant non‐small cell lung cancer patients treated with third‐generation EGFR tyrosine kinase inhibitors

Zhang, Z., Xue, J., Yang, Y., Fang, W., Huang, Y., Zhao, S., Luo, F., Cao, J., Zeng, K., Ma, W., et al. (2024) · MedComm · doi:10.1002/mco2.586 · Cited by 6

Somatic mutation subtypes of lung adenocarcinoma in East Asian reveal divergent biological characteristics and therapeutic vulnerabilities

Choong, W.-K., & Sung, T. (2021) · iScience · doi:10.1016/j.isci.2021.102522 · Cited by 6

TP53 Alterations Are Associated With Poor Response to Lenvatinib in Patients With Advanced Thyroid Cancer

Cirello, V., Colombo, C. M., Tosi, D., Manzo, A., Borghi, M. O., Gianelli, U., Gazzano, G., Ferrero, S., Dionigi, G., Persani, L., et al. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaf056 · Cited by 5

Role of TP53 Mutations and EGFR Amplification in Risk Stratification of Early‐Stage EGFR ‐Mutated Non‐Small Cell Lung Cancer With Immunohistochemistry as a Surrogate Marker

Kim, M., Park, G. S., Lee, K. Y., Moon, S. W., & Sung, Y. E. (2025) · Thoracic Cancer · doi:10.1111/1759-7714.70058 · Cited by 6

Erlotinib as a salvage treatment after gefitinib failure for advanced non-small-cell lung cancer patients with brain metastasis

Dong, Y. Q., Li, Q., Miao, Q., & Li, D. (2021) · Medicine · doi:10.1097/md.0000000000026450 · Cited by 5

Investigation on the prognostic impact of concurrent genomic alterations in crizotinib-treated EML4-ALK-rearranged advanced non-small cell lung cancer patients

Zheng, J., Zhu, Y., Sun, K., Shen, Q., Wang, Y., Cao, H., Lizaso, A., Yu, B., Lin, J., Chen, S., et al. (2020) · Lung Cancer · doi:10.1016/j.lungcan.2020.05.026 · Cited by 5

Multiple Resistance Mechanisms to Tyrosine Kinase Inhibitors in EGFR Mutated Lung Adenocarcinoma: A Case Report Harboring EGFR Mutations, MET Amplification, and Squamous Cell Transformation

Bruno, R., Re, M. D., Cucchiara, F., Petrini, I., Alì, G., Crucitta, S., Proietti, A., Valleggi, S., Chella, A., Danesi, R., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.674604 · Cited by 5

Successful treatment of an osimertinib-resistant lung adenocarcinoma with an exon 18 EGFR mutation (G719S) with afatinib plus bevacizumab

Tamiya, M., Kunimasa, K., Nishino, K., Matsumoto, S., Kawachi, H., Kuno, K., Inoue, T., Kuhara, H., Imamura, F., Goto, K., et al. (2021) · Investigational New Drugs · doi:10.1007/s10637-020-00966-7 · Cited by 5

Circulating Tumour DNA in Patients With EGFR ‐Mutated Non‐Small‐Cell Lung Cancer and Early Disease Progression After First‐Line Osimertinib Treatment: The ELUCIDATOR Multicentre Prospective Observational Study

Tamiya, A., Mizumori, Y., Osuga, M., Isa, S., Taniguchi, Y., Nakamura, K., Harada, D., Shinohara, T., Yanai, H., Nakatomi, K., et al. (2025) · Cancer Medicine · doi:10.1002/cam4.70861 · Cited by 4

Dacomitinib in the treatment of EGFR-mutated non-small cell lung cancer with brain metastases: an open-label, multicenter, phase II study

Yu, Y., Pan, Y., Zhou, J., Mu, S., & Lu, S. (2025) · Lung Cancer · doi:10.1016/j.lungcan.2025.108710 · Cited by 4

[Lung Squamous Cell Carcinoma with EML4-ALK Fusion and TP53 Co-mutation Treated with Ensartinib: A Case Report and Literature Review].

Lv, D., Xu, C., Wang, C., & Sang, Q. (2023) · PubMed Central · doi:10.3779/j.issn.1009-3419.2023.106.03 · Cited by 4

Prognostic and predictive effects of TP53 co-mutation in patients with non-small cell lung cancer with rare treatable driver mutations

Feng, J., Hueniken, K., Fan, Z. J., Zhan, L. J., Faour, E., Corke, L., Alghabban, A., Leighl, N. B., Liu, G., Bradbury, P. A., et al. (2025) · Lung Cancer · doi:10.1016/j.lungcan.2025.108452 · Cited by 4

Non-invasive identification of TKI-resistant NSCLC: a multi-model AI approach for predicting EGFR/TP53 co-mutations

Li, J., Xu, R., Wang, D., Liang, Z., Li, Y., Wang, Q., Bi, L., Qi, Y., Zhou, Y., & Li, W. (2025) · BMC Pulmonary Medicine · doi:10.1186/s12890-025-03805-8 · Cited by 4

Identification of TCR rearrangements specific for genetic alterations in EGFR-mutated non-small cell lung cancer: results from the ADJUVANT-CTONG1104 trial

Chen, C.-T., Liu, S., Chen, Y., Ou, Q., Bao, H., Xu, L., Zhang, Y.-K., Zhang, J.-T., Zhong, W., Zhou, Q., et al. (2022) · Cancer Immunology and Immunotherapy · doi:10.1007/s00262-022-03330-1 · Cited by 3

Concomitant TP53 mutation in early-stage resected EGFR-mutated non-small cell lung cancer: a narrative approach in a genetically admixed Brazilian cohort

Rúgolo, J. R. M., Baldavira, C. M., Prieto, T. G., Olivieri, E. H. R., Fabro, A. T., Rainho, C. A., Castelli, E. C., Ribolla, P. E. M., Ab’Saber, A. M., Takagaki, T. Y., et al. (2023) · Brazilian Journal of Medical and Biological Research · doi:10.1590/1414-431x2023e12488 · Cited by 4

Outcomes in non‐small cell lung cancer with uncommon epidermal growth factor receptor L858 substitutions under first‐line epidermal growth factor receptor tyrosine kinase inhibitors: A large real‐world cohort study

Shao, Y., Zhang, J., Feng, Z., Wu, W., Zhao, X., Zhu, M., Xiao, Y., Pang, J., Zhu, J., Qu, H., et al. (2024) · Cancer Science · doi:10.1111/cas.16250 · Cited by 3

Association of TP53 gain-of-function mutations with early osimertinib resistance in epidermal growth factor receptor-mutant lung adenocarcinoma

Ibusuki, R., Iwama, E., Shimauchi, A., Kawano, H., Tsuneoka, Y., Hashisako, M., Harada, T., Tsuchiya‐Kawano, Y., Nakatomi, K., Furuyama, K., et al. (2026) · ESMO Open · doi:10.1016/j.esmoop.2026.108018 · Cited by 3

Role of TP53 mutations in predicting response to TKI treatment in EGFR-mutated NSCLC patients.

Ulivi, P., Canale, M., Petracci, E., Chiadini, E., Dazzi, C., Capelli, L., Gamboni, A., Casanova, C., Papi, M., Mariotti, M., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.34.15_suppl.9052 · Cited by 4

Concomitant TP53 Mutation Confers Worse Prognosis in EGFR-Mutated Non-Small Cell Lung Cancer Patients Treated with TKIs

Canale, M., Petracci, E., Delmonte, A., Bronte, G., Chiadini, E., Ludovini, V., Dubini, A., Papi, M., Baglivo, S., Luigi, N. D., et al. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9041047 · Cited by 76

P3.02b-006 Role of TP53 Mutations in Determining Primary Resistance to First-Line Tyrosine Kinase Inhibitors in EGFR-Mutated NSCLC Patients

Ulivi, P., Canale, M., Delmonte, A., Petracci, E., Chiadini, E., Dazzi, C., Papi, M., Capelli, L., Casanova, C., Luigi, N. D., et al. (2017) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.11.1673

TP53 mutations predicts worse prognosis in EGFR-mutated NSCLC patients receiving TKIs in first- or further line of treatment

Canale, M., Luigi, N. D., Petracci, E., Delmonte, A., Ludovini, V., Dubini, A., Baglivo, S., Minenza, E., Chiadini, E., Landi, L. M., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz260.056

Concurrent TP53 mutations predict poor outcomes of EGFR-TKI treatments in Chinese patients with advanced NSCLC

Hou, H., Qin, K., Yu, L., Zhang, C., Liu, D., Jiang, H., Liu, K., Zhu, J., Lv, H., Li, T., et al. (2019) · Cancer Management and Research · doi:10.2147/cmar.s201513 · Cited by 78